Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener klinische Wochenschrift
Erschienen in:

01.07.2012 | original article

Intraindividual differences between two simultaneous glucose measurement systems in type 2 diabetic patients

verfasst von: Lars Stechemesser, MD, Agnes Hammerschmied, Brigitta Gappmayer, Mynda Schreuer, Raimund Weitgasser

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 13-14/2012

Einloggen, um Zugang zu erhalten

Summary

Aims

Continuous glucose measurement systems are an established tool to support diabetes therapy. Because of different technical solutions one can propose different potential limitations in daily practice. So we tried to identify the accuracy of two different devices head to head in daily routine to point out individual characteristics.

Methods

We included 24 patients with type 2 diabetes mellitus to wear the GlucoDay and the MiniMed continuous glucose measurement system at the same time for 48 h. We examined the mean differences in simultaneous glucose measurements, the confidence intervals were calculated by standard methods based on the t-distribution.

Results

Comparison of glucose levels of both continuous glucose measurement systems showed that there was a tendency for higher glucose levels measured by the GlucoDay device. These differences were dependent on the time of the day. The absolute difference between two consecutive glucose measurements was higher for the GlucoDay system what means a somehow higher fluctuation of the GlucoDay measurements.

Conclusions

The differences in intraindividual comparison of the GlucoDay and the MiniMed continuous glucose measurement systems in type 2 diabetic patients may be taken into account when using different systems for detection of nocturnal hypoglycemia and the observation of trends used for therapeutic decisions.
Vorheriger Artikel Evaluation of atrial electromechanical delay and left atrial mechanical function in patients with obstructive sleep apnea
Nächster Artikel Attempted suicide under high dose dopaminergic therapy including apomorphine
Literatur
1.
Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan D, Peterson CM, et al. Tests of glycemia in diabetes. Diabetes Care. 2004 Jan;27 Suppl 1:S91–3.CrossRef
2.
Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan D, Peterson CM, et al. Tests of glycemia in diabetes. Diabetes Care. 2004 Jul;27(7):1761–73.PubMedCrossRef
3.
Howe-Davies S, Simpson RW, Turner RC. Control of maturity-onset diabetes by monitoring fasting blood glucose and body weight. Diabetes Care. 1980 Sept–Oct;3(5):607–10.PubMedCrossRef
4.
Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care. 1997 Dec;20(12):1822–6.PubMedCrossRef
5.
Coster S, Gulliford MC, Seed PT, Powrie JK, Swaminathan R. Self-monitoring in type 2 diabetes mellitus: a meta-analysis. Diabet Med. 2000 Nov;17(11):755–61.PubMedCrossRef
6.
Welschen LM, Bloemendal E, Nijpels G, Dekker JM, Heine RJ, Stalman WA, et al. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review. Diabetes Care. 2005 Jun;28(6):1510–7.PubMedCrossRef
7.
Logtenberg SJJ, Kleefstra N, Hortensius J, Van Der Bijl JJ, Groenier KH, Houweling ST, et al. Effect of self-monitoring of blood glucose in patients with type 2 diabetes treated with oral medication on quality of life parameters: a 1 year randomized controlled trial. Abstract 85, 45th EASD Annual meeting of the European Association for the Study of Diabetes, Diabetologia. 2009;52 Suppl 1:S41.
8.
Nauck MA, Heinemann L, Gutzeit M, Haastert B, Petrick S, Trautner C, et al. A randomized, controlled trial of blood-glucose self-monitoring in type 2 diabetic patients receiving conventional insulin treatment. Abstract 86, 45th EASD Annual meeting of the European Association for the Study of Diabetes, Diabetologia. 2009;52 Suppl 1:S41–2.
9.
Garg S, Zisser H, Schwartz S, Bailey T, Kaplan R, Ellis S, et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor. Diabetes Care. 2006 Jan;29(1):44–50.PubMedCrossRef
10.
Leinung M, Thompson S, Nardacci E. Benefits of continuous glucose monitor use in clinical practice. Endocr Pract. 2010 May-Jun;16(3):371–5.PubMedCrossRef
11.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Weinzimer S, Miller K, Beck R, Xing D, Fiallo-Scharer R, Gilliam LK, et al. Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation continuous glucose monitoring (JDRF-CGM) trial. Diabetes Care. 2010 Jan;33(1):17–22.CrossRef
12.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Bode B, Beck RW, Xing D, Gilliam L, Hirsch I, Kollman C, et al. Sustained benefit of continuous glucose monitoring on A1C, glucose profiles, and hypoglycemia in adults with type 1 diabetes. Diabetes Care. 2009 Nov;32(11):2047–9.CrossRef
13.
Cosson E, Hamo-Tchatchouang E, Dufaitre-Patouraux L, Attali JR, Paris J, Schaepelynck-Balicar P. Multicentre, randomised, controlled study of the impact of continuous sub-cutaneous glucose monitoring (GlucoDay) on glycaemic control in type 1 and type 2 diabetes patients. Diabetes Metab. 2009 Sep;35(4):312–8.PubMedCrossRef
14.
Chico A, Vidal-Rios P, Subira M, Novialis A. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care. 2003 Apr;26(4):1153–7.PubMedCrossRef
15.
Monsod TP, Flanagan DE, Rife F, Saenz R. Do sensor glucose levels accurately predict plasma glucose concentrations during hypoglycemia and hyperinsulinemia? Diabetes Care. 2002 May;25(5):889–93.PubMedCrossRef
16.
Garg SK, Schwartz S, Edelmann SV. Improved glucose excursions using an implantable real-time continuous glucose sensor in adults with type 1 diabetes. Diabetes Care. 2004 Mar;27(3):734–8.PubMedCrossRef
17.
Guerci B, Floriot M, Bohme P, Durain D, Benichou M, Jellimann S, et al. Clinical performance of CGMS in type 1 diabetic patients treated by continuous subcutaneous insulin infusion using insulin analogs. Diabetes Care. 2003 Mar;26(3):582–9.PubMedCrossRef
18.
Maran A, Crepaldi C, Tiengo A, Grassi G, Vitali E, Pagano G, et al. Continuous subcutaneous glucose monitoring in diabetic patients: a multicenter analysis. Diabetes Care. 2002 Feb;25(2):347–52.PubMedCrossRef
19.
Mastrototaro JJ, Gross TM. Reproducibility of the continuous glucose monitoring system matches previous reports and the intended use of the product. Diabetes Care. 2003 Jan;26(1):256.PubMedCrossRef
20.
Gross TM, Mastrototaro JJ. Efficacy and reliability of the continuous glucose monitoring system. Diabetes Technol Ther. 2000;2 Suppl 1:S19–26.CrossRef
21.
Bode BW, Gross TM, Thornton KR, Mastrototaro JJ. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. Diabetes Res Clin Pract. 1999 Dec;46(3):183–90.PubMedCrossRef
22.
Tanenberg R, Bode B, Lane W, Levetan C, Mestman J, Harmel AP, et al. Use of the continuous glucose monitoring system to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial. Mayo Clin Proc. 2004 Dec;79(12):1521–6.PubMedCrossRef
23.
Deiss D, Bolinder J, Riveline JP, Battelino T, Bosi E, Tubiana-Rufi N, et al. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care. 2006 Dec;29(12):2730–2.
24.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008 Oct 2;359(14):1464–76.PubMedCrossRef
25.
Wentholt IM, Vollebregt MA, Hart AA, Hoekstra JB, DeVries JH. Comparison of a needle-type and a microdialysis continuous glucose monitor in type 1 diabetic patients. Diabetes Care. 2005 Dec;28(12):2871–6.PubMedCrossRef
Metadaten
Titel
Intraindividual differences between two simultaneous glucose measurement systems in type 2 diabetic patients
verfasst von
Lars Stechemesser, MD
Agnes Hammerschmied
Brigitta Gappmayer
Mynda Schreuer
Raimund Weitgasser
Publikationsdatum
01.07.2012
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 13-14/2012
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-012-0201-6

Weitere Artikel der Ausgabe 13-14/2012

Jahrestagung 2012 der Österreichischen Gesellschaft für Pneumologie

  • Abstracts

Attempted suicide under high dose dopaminergic therapy including apomorphine

  • case report

Effective penile block for circumcision in adults

  • original article

Evaluation of atrial electromechanical delay and left atrial mechanical function in patients with obstructive sleep apnea

  • original article

Evaluation of biochemical, hematological, and thyroid function parameters in nondipper and dipper hypertensive patients

  • original article

Österreichische Gesellschaft für Endokrinologie und Stoffwechsel

  • mitteilungen der gesellschaft